Pharmacokinetic correlates of clinical response in a naturalistic sample of escitalopram-treated patients

References

• Practice guideline for major depressive disorder in adults: American Psychiatric Association. AJP. 1993;150(4):1–26. doi: 10.1176/ajp.150.4.1
   Google Scholar
• Depression in adults: treatment and management. 2022 [cited 2023 Sep 25]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK583074/.
   Google Scholar
• Gautam S, Jain A, Gautam M, et al. Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD). Indian J Psychiatry. 2017 [cited 2023 Sep 25]; 59:S67–S73. doi: 10.4103/0019-5545.196975
   PubMed Web of Science ®Google Scholar
• Diaz-Camal N, Cardoso-Vera JD, Islas-Flores H, et al. Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: a review. Sci Total Environ. 2022;829 [cited 2023 Sep 25]. [Internet] Available from: https://pubmed.ncbi.nlm.nih.gov/35318057/
   PubMed Web of Science ®Google Scholar
• Escitalopram - Drug Usage Statistics, ClinCalc DrugStats Database [Internet]. [cited 2023 Sep 26]. Available from: https://clincalc.com/DrugStats/Drugs/Escitalopram
   Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018 [cited 2023 Sep 25];51:9–62. doi: 10.1055/s-0043-116492
   PubMed Web of Science ®Google Scholar
• Dressman JB, Thelen K. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009 [cited 2023 Sep 25];61:541–558. doi: 10.1211/jpp/61.05.0002
   PubMed Web of Science ®Google Scholar
• Eichentopf L, Hiemke C, Conca A, et al. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: blood concentrations, clinical effects and serotonin transporter occupancy. Front Psychiatry. 2022 [cited 2023 Sep 22]; 13. [Internet] Available from: https://pubmed.ncbi.nlm.nih.gov/36325531/
   PubMed Web of Science ®Google Scholar
• Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009 [cited 2023 Sep 26];169:124–131. doi: 10.1016/j.psychres.2009.06.004
   PubMed Web of Science ®Google Scholar
• Kuo HW, Liu SC, Tsou HH, et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics. 2013 [cited 2023 Sep 26];14:1191–1201. doi: 10.2217/pgs.13.105
   PubMed Web of Science ®Google Scholar
• Hodgson K, Tansey K, Dernovšek MZ, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014 [cited 2023 Sep 26];28:133–141. doi: 10.1177/0269881113512041
   PubMed Web of Science ®Google Scholar
• Tadić A, Wachtlin D, Berger M, et al. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression–the EMC trial. Eur Neuropsychopharmacol. 2016 [cited 2023 Sep 26];26:705–716. doi: 10.1016/j.euroneuro.2016.02.003
   PubMed Web of Science ®Google Scholar
• Florio V, Porcelli S, Saria A, et al. Escitalopram plasma levels and antidepressant response. Eur Neuropsychopharmacol. 2017 [cited 2023 Sep 26];27:940–944. doi: 10.1016/j.euroneuro.2017.06.009
   PubMed Web of Science ®Google Scholar
• Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019 [cited 2023 Oct 15];13:S31–S34. doi: 10.4103/sja.SJA_543_18
   PubMed Web of Science ®Google Scholar
• Neuner T, Hübner-Liebermann B, Haen E, et al. Completed suicides in 47 psychiatric hospitals in Germany – results from the AGATE-Study. Pharmacopsychiatry. 2011;44:324–330. doi: 10.1055/s-0031-1284428
   PubMed Web of Science ®Google Scholar
• Kuzin M, Gardin F, Götschi M, et al. Changes in psychotropic drug blood levels after SARS-CoV-2 vaccination: a two-center cohort study. Ther Drug Monit. 2023;45(6):792–796. doi: 10.1097/FTD.0000000000001118
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Strømmen M, Krabseth H-M, et al. Effects of sleeve Gastrectomy and Roux-en-Y Gastric Bypass on escitalopram pharmacokinetics: a cohort study. Therapeutic Drug Monitoring. 2023;45(6):805–812. doi: 10.1097/FTD.0000000000001114
   PubMed Web of Science ®Google Scholar
• Kuzin M, Hean E, Kuzo N, et al. Changes in psychotropic drug blood levels after SARS-CoV-2 vaccination: a two-center cohort study. Ther Drug Monit. 2023;45(6):792–796. doi: 10.1097/FTD.0000000000001118
   PubMed Web of Science ®Google Scholar
• Fischer-Barnicol D, Lanquillon S, Haen E, et al. Typical and atypical antipsychotics – the misleading dichotomy. Neuropsychobiology. 2008;57:80–87. doi: 10.1159/000135641
   PubMed Web of Science ®Google Scholar
• Drug development and drug interactions | table of substrates, inhibitors and inducers | FDA [Internet]. [cited 2023 Sep 27]. Available from: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
   Google Scholar
• Deutsche Industrienorm 32645 [Internet]. [cited 2023 Sep 27]. Available from: https://www.din.de/de/mitwirken/normenausschuesse/nmp/veroeffentlichungen/wdc-beuth:din21:110729574
   Google Scholar
• Bioanalytical Method Validation Guidance for Industry | FDA [Internet]. [cited 2023 Sep 27]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry
   Google Scholar
• European Medicines Agency, ICH Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1). 2005.
   Google Scholar
• Greiner C, Hiemke C, Bader W, et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B. 2007;848:391–394. doi: 10.1016/j.jchromb.2006.10.058
   PubMed Web of Science ®Google Scholar
• Chan BKC. Data Analysis Using R Programming. Adv Exp Med Biol. 2018;1082:47–122. [cited 2023 Sep 27]. [Internet]Available from: https://pubmed.ncbi.nlm.nih.gov/30357717/
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don’t work. J Psychiatr Pract. 2014 [cited 2023 Sep 27];20:133–137. doi: 10.1097/01.pra.0000445247.54048.68
   PubMed Web of Science ®Google Scholar
• De Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013 [cited 2023 Oct 18];35:30–47. doi: 10.1097/FTD.0b013e31827ada88
   PubMed Web of Science ®Google Scholar
• Ruan CJ, Olmos I, Ricciardi C, et al. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: a literature review and a case series of 17 patients from 3 studies. Schizophr Res [Internet]. 2023 [cited 2023 Oct 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/37487869/
   Google Scholar
• Jukić MM, Haslemo T, Molden E, et al. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018 [cited 2023 Sep 22];175:463–470. doi: 10.1176/appi.ajp.2017.17050550
   PubMed Web of Science ®Google Scholar
• Wong WLE, Fabbri C, Laplace B, et al. The effects of CYP2C19 genotype on proxies of SSRI antidepressant response in the UK biobank. Pharmaceuticals (Basel). [cited 2023 Sep 29]. 2023;16:1277. doi: 10.3390/ph16091277
   PubMedGoogle Scholar
• Islam F, Marshe VS, Magarbeh L, et al. Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. Transl Psychiatry. 2022;12 [cited 2023 Sep 29]. InternetAvailable from: https://pubmed.ncbi.nlm.nih.gov/36068210/
   PubMed Web of Science ®Google Scholar
• Hiemke C. Concentration–effect relationships of psychoactive drugs and the Problem to Calculate Therapeutic Reference Ranges. Therapeutic Drug Monitoring. [cited 2024 Jan 20] 2019;41:(2)174–179. doi: 10.1097/FTD.0000000000000582
   PubMed Web of Science ®Google Scholar
• Tomita T, Yasui-Furukori N, Nakagami T, et al. The influence of 5-HTTLPR genotype on the Association between the plasma concentration and therapeutic effect of paroxetine in patients with Major depressive disorder. PLoS One. 2014 [cited 2024 Jan 10];9:e98099. doi: 10.1371/journal.pone.0098099
   PubMed Web of Science ®Google Scholar
• Umene-Nakano W, Yoshimura R, Ueda N, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2009 [cited 2024 Jan 11];24(12):1764–1771. doi: 10.1177/0269881109106899
   PubMed Web of Science ®Google Scholar
• Arakawa R, Stenkrona P, Takano A, et al. Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with Major depressive disorder: a PET study using [18F]FMeNER-D2. Int J Neuropsychopharmacol. 2019 [cited 2023 Sep 29];22:278–285. doi: 10.1093/ijnp/pyz003
   PubMed Web of Science ®Google Scholar
• Won ES, Chang HS, Lee HY, et al. Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean patients with Major depressive disorder. Neuropsychobiology. 2012 [cited 2024 Jan 11];66:221–229. doi: 10.1159/000341876
   PubMed Web of Science ®Google Scholar
• Lundberg J, Christophersen JS, Petersen KB, et al. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 2007 [cited 2023 Oct 3];10:777–785. doi: 10.1017/S1461145706007486
   PubMed Web of Science ®Google Scholar
• Steen NE, Aas M, Simonsen C, et al. Serum level of venlafaxine is associated with better memory in psychotic disorders. Schizophr Res 2015 [cited 2023 Oct 3];169:386–392. doi: 10.1016/j.schres.2015.10.021
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Haen E, Hiemke C, et al. Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol 2018 [cited 2023 Sep 29];33:322–329. doi: 10.1097/YIC.0000000000000234
   PubMed Web of Science ®Google Scholar
• De Carlo V, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res. 2016;240:421–430. doi: 10.1016/j.psychres.2016.04.034
   PubMed Web of Science ®Google Scholar
• Balestri M, Calati R, Souery D, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–232. doi: 10.1016/j.jad.2015.09.033
   PubMed Web of Science ®Google Scholar